References
- Anonymous (1996). Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology. J Clin Oncol, 14, 2843-77. https://doi.org/10.1200/JCO.1996.14.10.2843
- Bensouda Y, Andre F, Boulet T, et al (2009). Prevalence of elevated serum CA 15-3 at time of metastatic relapse of breast cancer and correlation with hormone receptor status. Bull Cancer, 96, 923-8
- Berruti A, Tampellini M, Torta M, et al (1994). Prognostic value in predicting overall survival of two mucinous markers: CA15-3 and CA 125 in breast cancer patients at first relapse of disease. Eur J Cancer, 30, 2082-4 https://doi.org/10.1016/0959-8049(94)00356-A
- Brekelmans CT (2003). Risk factors and risk reduction of breast and ovarian cancer. Curr Opin Obstet Gynecol, 15, 63-8. https://doi.org/10.1097/00001703-200302000-00010
- Busetto M, Vianello L, Franceschi R, Bolzan M (1995). CA 15-3 value and neoplastic disease predictivity in the follow-up for breast cancer. Tumour Biol, 16, 243-53. https://doi.org/10.1159/000217941
- Cengiz B, Atabekoglu C, Cetinkaya E, Cengiz SD (2003). Effect of hormone replacement therapy on serum levels of tumor mark¬ers in healthy postmenopausal women. Maturitas, 46,301-6. https://doi.org/10.1016/S0378-5122(03)00220-2
- Cheung K, Graves CRL, Robertson JFR (2000). Tumor marker measurements in the diagnosis and monitoring of breast cancer. Cancer Treat Rev, 26,91-102. https://doi.org/10.1053/ctrv.1999.0151
- Coveney EC, Geraghty JG, Sherry F, et al (1995). The clinical value of CEA and CA 15-3 in breast cancer management. Int J Biol Markers, 10, 35-41. https://doi.org/10.1177/172460089501000107
- Crump C, McIntosh MW, Urban N, Anderson G, Karlan BY (2000). Ovarian cancer tumor marker behavior in asymptomatic healthy women: implications for screening. Cancer Epidemiol Biomarkers Prev, 9, 1107-11.
- Dehaghani AS, Ghiam AF, Hosseini M, Mansouri S, Ghader A (2007). Factors Influencing Serum Concentration of CA125 and CA15-3 in Iranian Healthy Postmenopausal Women. Pathology Oncol Res, ?, 13360-364. https://doi.org/10.1007/BF02940317
- Duffy MJ (1999). CA 15-3 and related mucins as circulating markers in breast cancer. Ann Clin Biochem, 36, 579-86. https://doi.org/10.1177/000456329903600503
- Duffy MJ (2006). Serum tumor markers in breast cancer: Are they of clinical value? Clinical Chemistry, 52, 345-51 https://doi.org/10.1373/clinchem.2005.059832
- Elston CW, Ellis IO, Pinder SE (1999). Pathological prognostic factors in breast cancer. Crit Rev Oncol Haematol, 31, 209-23. https://doi.org/10.1016/S1040-8428(99)00034-7
- Gang Y, Adachi I, Ohkura H, (1985). CA15-3 is present as a novel tumor marker in the sera of patients with breast cancer and other malignancies. Gan To Kagaku Ryoho, 12, 2379-86
- Gion M, Boracchi P, Dittadi R, et al (2002). Prognostic role of serum CA15.3 in 362 node-negative breast cancers. An old player for a new game. Eur J Cancer, 38, 1181-8. https://doi.org/10.1016/S0959-8049(01)00426-9
- Hayes DF, Mesa Tejada R, Papsidero L, et al (1991). Prediction of prognosis in primary breast cancer by detection of a high molecular weight mucin-like antigen using monoclonal antibodies DF3, F36/22, and CU18: a Cancer and Leukemia Group B study. J Clin Oncol, 9, 1113-23. https://doi.org/10.1200/JCO.1991.9.7.1113
- Hayes DF, Zurawski VR, Kufe DW (1986). Comparison of circulating CA15-3 and carcinoembryonic antigen levels in patients with breast cancer. J Clin Oncol, 4, 1542-50. https://doi.org/10.1200/JCO.1986.4.10.1542
- Jordan breast cancer program: http://www.jbcp.jo/node/14
- Kikuchi K, Uematsu Y, Takada Y, et al (1987). Evaluation of tumor marker CA15-3 in breast cancer. Gan To Kagaku Ryoho, 14, 3095-100.
- Kobayashi S, Iwase H, Karamatsu S, et al (1989). The clinical value of serum CA15-3 assay postoperatively in breast cancer patients. Jpn J Surg, 19, 278-82. https://doi.org/10.1007/BF02471402
- Kochańska Dziurowicz A, Pasich R, Stanjek A, Gaweł Szostek V, T Jankowski (2000). Serum concentration of selected neoplasm markers: CA15-3, TPS and CEA in women with diagnosed breast benign disease. Ginekol Pol, 71, 1139-43
- Lumachi F, Basso SM, Brandes AA, Pagano D, Ermani M (2004). Relationship between tumor markers CEA and CA 15-3, TNM staging, estrogen receptor rate and MIB-1 index in patients with pT1-2 breast cancer. Anticancer Res, 24, 3221-4.
- McLaughlin R, McGrath J, Grimes H, Given HF (2000). The prognostic value of the tumor marker CA 15-3 at initial diagnosis of patients with breast cancer. Int J Biol Markers, 15, 340-2. https://doi.org/10.1177/172460080001500412
- Molina R, Jo J, Zanón G, et al (1996). Utility of C-erbB-2 in tissue and in serum in the early diagnosis of recurrence in breast cancer patients: comparison with carcinoembryonic antigen and CA 15.3. Br J Cancer, 74, 1126-31. https://doi.org/10.1038/bjc.1996.501
- Molina R, Jo J, Filella X, et al (1999). C-erbB-2, CEA and CA 15.3 serum levels in the early diagnosis of recurrence of breast cancer patients. Anticancer Res, 19, 2551-5.
- Nicolini A (2000). Carpi A. Postoperative follow-up of breast cancer patients: overview of progress in the use of tumor markers. Tumor Biol, 21, 235-48. https://doi.org/10.1159/000030129
- Pike MC, Pearce CL, Wu AH (2004) Prevention of cancers of the breast, endometrium and ovary. Oncogene, 23, 6379-91. https://doi.org/10.1038/sj.onc.1207899
- Rymer J, Morris EP (2000). Extracts from "Clinical evidence": Menopausal symptoms. BMJ, 321, 1516-9. https://doi.org/10.1136/bmj.321.7275.1516
- Seregni E, Botti C, Bajetta E, et al (1999). Bombardieri E: Hormonal regulation of MUC1 expression. Int J Biol Markers, 14, 29-35. https://doi.org/10.1177/172460089901400106
- Shering SG, Sherry F, McDermott EW, et al (1998). Preoperative CA15-3 concentrations predict outcome of patients with breast carcinoma. Cancer, 83, 2521-7. https://doi.org/10.1002/(SICI)1097-0142(19981215)83:12<2521::AID-CNCR17>3.0.CO;2-A
- Singletary SE, Allred C, Ashley P, et al (2002). Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol, 20, 3628-36. https://doi.org/10.1200/JCO.2002.02.026
- Tampellini M, Berruti A, Gerbino A, et al (1997). Relationship between CA15-3 serum levels and disease extent in predicting overall survival of breast cancer patients with newly diagnosed metastatic disease. Br J Cancer, 75, 698- 702. https://doi.org/10.1038/bjc.1997.124
- Taylor PJ, Burchell JM, Plunkett T, et al (2002). MUC1 and the immunobiology of cancer. J Mammary Gland Biol Neoplasia, 7, 209-21. https://doi.org/10.1023/A:1020360121451
- Theriault RL, Hortobagyi GN, Fritsche HA, et al (1989). The role of serum CEA as a prognostic indicator in stage II and III breast cancer patients treated with adjuvant chemotherapy. Cancer, 63, 828-35. https://doi.org/10.1002/1097-0142(19890301)63:5<828::AID-CNCR2820630506>3.0.CO;2-3
- Thompson JA, Grunert F, Zimmermann W (1991). Carcinoembryonic antigen gene family: molecular biology and clinical perspectives. J Clin Lab Anal, 5, 344-66. https://doi.org/10.1002/jcla.1860050510
- Thriveni K, Krishnamoorthy L, Ramaswamy G (2007). Correlation study of carcinoembryonic antigen & cancer antigen 15.3 in pretreated female breast cancer patients. Indian J Clin Biol, 22, 57-60 https://doi.org/10.1007/BF02912882
Cited by
- Breast Cancer in Morocco: A Literature Review vol.15, pp.3, 2014, https://doi.org/10.7314/APJCP.2014.15.3.1067
- Usefulness of Salivary and Serum Auto-antibodies Against Tumor Biomarkers HER2 and MUC1 in Breast Cancer Screening vol.17, pp.1, 2016, https://doi.org/10.7314/APJCP.2016.17.1.335
- Correlates of circulating ovarian cancer early detection markers and their contribution to discrimination of early detection models: results from the EPIC cohort vol.10, pp.1, 2017, https://doi.org/10.1186/s13048-017-0315-6